Needham Reiterates Buy on Cara Therapeutics, Maintains $22 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Cara Therapeutics (NASDAQ:CARA) and maintained a price target of $22.
August 08, 2023 | 11:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cara Therapeutics has received a reiterated 'Buy' rating from Needham analyst Joseph Stringer, with a maintained price target of $22.
The reiterated 'Buy' rating and maintained price target by Needham analyst could potentially boost investor confidence in Cara Therapeutics, leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100